OUR PORTFOLIO
MintPharma Capital currently holds a diversified portfolio of six companies spanning the healthcare, biotech, and life sciences sectors.
We actively partner with founders and management teams to accelerate growth, enhance value, and position each business for long-term success.
Each investment reflects our commitment to advancing innovation and sustainable growth across industries that improve health outcomes and scientific progress.
PLEOPHARMA
Over 1.3M people were treated last year with a total population of Cannabis Use Disorder of almost 19M per US Government data. This population is growing at almost ~20% a year due to the legalization of Cannabis.
​
Used multiple times a day. high potency Cannabis down regulates the CB-1 receptors and the reward center in the brain which can cause withdrawal symptoms similar to nicotine and other addictive substances when use is discontinued. Currently there is no FDA approved drug to help people who would like to cut back or quit to mitigate withdrawal symptoms and cravings due to discontinuation.
​
The potency of Cannabis today has enabled a significantly different addictive potential than the Cannabis that was produced and used 20 years ago due to the percentage of THC moving from >5% to 40-100% today.
​
If approved, PleoPharma's drug candidate will reduce payor cost significantly by providing the first outpatient Medication Assisted Therapy vs. inpatient detox while delivering an ideal patient friendly Medication Assisted Therapy.
NOXX THERAPEUTICS
NOXX Therapeutics is a preclinical company focused on developing monoclonal antibodies to improve where small molecules have failed in validated mechanism of action within the Oncology space.
Specifically creating an environment where cannot suppress and kill key immune cells, i.e., NK cells and T cells, thereby allowing the tumor to avoid the immune system.
Significant research, > than 350 publications, and > 20 clinical trials have demonstrated a significant survival benefit for patients around this disruptive approach.
ICaPath /EYE-SEE-A-PATH/
ICaPath is pioneering breakthrough therapies designed to revolutionize cancer treatment through its proprietary nanoparticle immunotherapy delivery platform.
This breakthrough approach enables cytokines to be delivered in a highly controlled and personalized manner.
The result is sustained immune efficacy that could lead to a substantial paradigm shift on how cancer is being treated.
MYOSIN THERAPEUTICS
A late-stage preclinical company leveraging inhibition of non-muscle Myosin nanomotors to treat disease. The company has received over $20 million in NIH grant funding to take MT-125 for Glioblastoma and MT-110 for Stimulant Use Disorder through phase 1. Data is expected in Q1/Q2 of 2025. This platform technology (if successful) can be used to treat a host of disease types that leverage Myosin nanomotors.
​
MyoKardia, a cardiovascular company also using myosin to treat disease, was acquired for $13.1 billion dollars by Bristol-Myers Squibb in phase 3. MyoKardia’s drug candidate was recently by the FDA as a first leveraging Myosin as a drug target and further supporting our conviction in this asset.
​
Founded at Scripps/University of Florida in Jupiter Florida by 3 Scripps professors, MintPharma Capital lead Myosin’s first equity raise. MintPharma Capital’s approach involves placing experienced management from the BioTech industry to support in Myosin’s existing management team in the areas of finance, legal, IP, quality assurance and regulatory while providing director oversight at the board level.
VYCELLIX
Headquartered in Tampa, Florida, with scientific operations in Stockholm, Sweden, Vycellix has developed a broad suite of cell therapy engineering solutions with the mission to deploy these collective tools to develop and commercialize optimized, next-generation T cell and natural killer (NK) cell-based cancer therapies.
Leveraging the Company’s transformational VY-UC universal cell technology, Vycellix is engineering immune-privileged effector cells without altering the components that control self-recognition (HLA) and obviating the need for immune-suppressive drugs in the contexts of allogeneic cell therapies, hence redefining “off-the-shelf” donor-cell-based treatment strategies.
Beyond VY-UC, the Company’s cell engineering tools represent ideal solutions to enhance gene delivery, accelerate cell expansion, amplify cell potency, and optimize muti-antigen engagement.
ASTROCYTE PHARMACEUTICALS
Astrocyte is developing AST-004, a novel small-molecule cerebroprotectant that has shown impressive efficacy in both small and large animal models.
The company has completed Phase 1 safety trials and is now launching a Phase 2 clinical trial in athletes with concussions, with initial biomarker and efficacy data expected by June 2026.
​
They’ve also have been accepted into NIH StrokeNet, which is expected to support a large stroke trial with ~$25m in non-dilutive funding.
